Ironorm

Ferrous Sulfate

Method of action: Antianemic, Hematopoietic

Treatment option: Anemia, Pregnancy, Iron Deficiency, Labor And Delivery

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ironorm

Ironorm is a pharmaceutical preparation classified as a hematinic, belonging to the general class of Oral Iron Supplements. It is designed to address conditions resulting from insufficient iron stores, which are necessary for many vital functions, including red blood cell production.

Property	Description
Active Ingredient	Ferrous Sulfate (FeSO4)
Form	Oral Solution (Drops/Syrup), Capsules, or Tablets
Pharmacological Class	Hematinic / Oral Iron Supplement
Common Purpose	Restores iron levels to address deficiency
Origin	Synthetic Agent

Classification and Available Forms

The medication utilizes Ferrous Sulfate as its source of elemental iron. Iron preparations, such as those based on Ferrous Sulfate, are considered essential medicines for the treatment and prevention of anemia. Ironorm is typically a combination product, integrating the iron salt with other essential chemical substances such as Ascorbic Acid (Vitamin C) and Folic Acid (Vitamin B9). Its common presentation as an Oral Solution is often utilized for accurate dosing in infants and children.

Core Composition and the Role of Active Ingredients

The strategic choice of Ferrous Sulfate ensures a readily bioavailable form of iron. The formula's inclusion of Ascorbic Acid improves the absorption of non-heme iron in the gastrointestinal tract. This formulation is designed to enhance the body's ability to utilize the supplied iron efficiently. Furthermore, the inclusion of co-factors like Folic Acid and other B vitamins supports broader nutritional health relevant to blood formation processes, distinguishing it from simpler, single-ingredient iron salts.

General Purpose: Addressing Iron and Red Blood Cell Needs

The general purpose of Ironorm is to provide the necessary material to combat symptoms related to low iron, such as pervasive fatigue. By supplying the elemental iron, Ironorm directly contributes to the synthesis of hemoglobin, an essential component required for red blood cell synthesis. The product's use is common during periods of increased demand, such as in pregnant females, where the need for iron supplementation is significantly elevated. This restoration of oxygen-carrying capacity via the blood is the primary benefit, which serves to alleviate the symptoms of iron deficiency anaemia.

Regulatory References

WHO Essential Medicines List

What side effects are possible with Ironorm?

Possible Side Effects and Safety Information

The safety profile of Ironorm, an oral iron supplement containing Ferrous Sulfate, is primarily characterized by effects concerning the Gastrointestinal System, as consistently documented in official regulatory sources. These effects are classified as common or occasional adverse reactions.

Regulatory Classification of Common Reactions

The most frequently documented adverse reactions, according to the official safety framework, include nausea, constipation, diarrhea, abdominal pain, and epigastric discomfort. A very common and expected outcome is the discoloration of stools, which typically appear black or green. For liquid forms, regulatory labels also note the possibility of temporary staining of the teeth.

Serious Adverse Reactions and Safety Constraints

The most critical safety warning explicitly stated by government health authorities relates to the risk of accidental overdose. Ingestion of excessive amounts of iron-containing products is documented as a leading cause of fatal poisoning in children under six years of age. Signs of severe toxicity requiring immediate attention include the onset of shock, seizures, severe vomiting (potentially bloody), or tarry stools.

Population-Specific Safety Notes

The product is contraindicated in individuals with established iron overload conditions, such as hemochromatosis or hemosiderosis, or those with certain active gastrointestinal diseases, including peptic ulceration or ulcerative colitis. Furthermore, regulatory documents detail that acute toxicity symptoms may follow a biphasic pattern, which is crucial for recognizing the course of severe ingestion events.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Ironorm (Ferrous Sulfate)

Immediate action is mandatory upon any suspected ingestion. Regulatory guidance explicitly states that seeking immediate medical attention and contacting emergency services is required due to the potential for fatal poisoning. Hospital monitoring and observation, often for 24 to 48 hours, is required following significant exposure.

Classification Aspect	Official Regulatory Statements
Documented Manifestations	Symptoms include aggressive vomiting (potentially bloody), diarrhea (tarry), severe abdominal pain, lethargy, hypotension, and laboratory evidence of metabolic acidosis.
Severe Outcomes	Risk of circulatory collapse, shock, convulsions, coma, and delayed organ damage such as hepatic necrosis and gastrointestinal stricture.
Antidote and Treatment	The specific chelating agent deferoxamine is documented as the antidote for severe iron poisoning. Management is primarily symptomatic and supportive, including fluid resuscitation.
Population Risk	Accidental overdose in children is a leading cause of fatal poisoning. Pediatric patients may follow a dangerous biphasic course, with initial improvement preceding severe clinical relapse.

Official regulatory documents define the overdose profile by its potential for severe systemic toxicity, which necessitates an immediate and aggressive clinical response. This toxicity underpins the mandatory requirement to seek urgent medical help for any suspected exposure, particularly in the pediatric population.

Therapeutic Uses of Ironorm

Ironorm is applied across therapeutic domains where additional symptomatic support is needed, focusing on easing discomfort and functional strain. In clinical contexts, such as the management of iron-deficient states, it is commonly used to help with the restoration of essential levels.

Main Uses and Supportive Benefits

Ironorm is generally used for managing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. These uses are relevant across conditions presenting with acute episodes and recurrent manifestations. It helps address symptom clusters that may become intense or disruptive, providing supportive relief.

The key benefit is that the medication contributes to improved comfort during periods of heightened symptoms, which helps patients cope more steadily with symptom fluctuations. As part of supportive care, it assists with maintaining functional stability and supports general well-being during symptomatic phases when symptoms are more noticeable.

Quick Fact: Relief for Functional Strain

Regulatory References

NHS guidance on Iron deficiency anaemia

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Ironorm is an oral iron supplement whose use is defined by official regulatory criteria, primarily related to iron levels and underlying health conditions.

Category	Official Regulatory Status (Based on FDA/EMA/NHS Labels)
Populations for whom use is allowed	Adults and the Pediatric Population (Children and Adolescents). Pregnant Females and Breastfeeding Females.
Populations for whom use is contraindicated	Patients with Hemochromatosis or other Iron Overload conditions. Patients with Anemias Not Caused by Iron Deficiency (e.g., Hemolytic Anemia). Patients with known Hypersensitivity to ferrous sulfate or excipients.
Age-related eligibility rules	Pediatric use is permitted, but regulatory labels include a mandatory warning regarding the risk of fatal poisoning in children from accidental overdose.
Condition-specific eligibility rules	Contraindicated in patients with Active Peptic Ulceration or existing severe Ulcerative Colitis/Regional Enteritis. Use requires caution in patients with severe hepatic or renal impairment.

Eligibility-related restrictions include a prohibition on use for patients receiving repeated blood transfusions due to the risk of iron accumulation. The use is officially permitted during both pregnancy and lactation. Use in older adults is generally acceptable but requires consideration due to potential co-morbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ironorm, which contains Ferrous Sulfate, has a documented interaction profile primarily based on pharmacokinetic interactions where iron, a polyvalent cation, binds to other substances in the digestive tract, altering their absorption or its own. This requires specific constraints as documented by regulatory authorities.

Formally Contraindicated Combinations

Oral iron is formally contraindicated with Intravenous Iron Preparations due to the documented risk of systemic iron overload. Co-administration with Dimercaprol is also advised to be avoided due to the documented risk of nephrotoxicity.

Administration Timing Requirements

To mitigate reduced absorption and ensure efficacy, regulatory documents mandate time separation between Ironorm and certain medicines:

Quinolone Antibiotics (e.g., Ciprofloxacin): Must be separated by at least two hours before or six hours after the oral iron dose.
Tetracycline Antibiotics and L-Thyroxine: Must be separated by at least two hours from the oral iron dose.

Exposure-Modifying and Food Interactions

Iron preparations decrease the serum exposure of certain Antivirals (e.g., Bictegravir) by cation binding. Conversely, Ascorbic Acid (Vitamin C), often included in Ironorm, is officially documented to increase iron absorption. Antacids and Calcium-containing products can reduce iron absorption, while Polyphenol-containing beverages (e.g., tea, coffee) are documented to interfere with absorption.

Mechanism of Action

Ironorm delivers elemental iron in the form of a ferrous salt (Fe^2+) to the gastrointestinal tract. This form of iron, which is more soluble and readily absorbed than the ferric (Fe^3+) state, is the primary biological target for intestinal uptake. The ferrous ions are transported across the apical membrane of the duodenal and jejunal enterocytes via the Divalent Metal Transporter 1 (DMT1).

Inside the enterocyte, iron can be temporarily stored by the protein ferritin or exported into the systemic circulation. Export into the plasma is mediated by the basolateral efflux channel ferroportin. Once in the plasma, the exported Fe^2+ is rapidly oxidized to Fe^3+ by the ferroxidase enzyme hephaestin or by ceruloplasmin, allowing the ion to be complexed and transported by the plasma protein transferrin.

Transferrin delivers the iron to target tissues, primarily the bone marrow, where it is incorporated into protoporphyrin to form heme. The heme molecule then binds with globin chains to synthesize hemoglobin. This process supports erythropoiesis by providing the central, essential mineral for the formation of functional hemoglobin, thereby increasing the oxygen-carrying capacity within the circulatory system.

Dosage and Administration Information

How to Use Ironorm

Ironorm, an oral iron supplement, is administered through the oral route. The medicine is commonly available as an oral tablet (200 mg to 325 mg ferrous sulfate), an oral solution, or in extended-release forms. The usage pattern is designed to support proper absorption and effectiveness.

Administration Guidelines

Instruction Category	Guideline (Ferrous Sulfate)
Standard Dosing	Adults: The typical therapeutic regimen is 200 mg to 325 mg ferrous sulfate (approximately 65 mg elemental iron) taken up to three times per day, or 600 mg/day in divided doses.
Frequency	Dosing may be set for once daily, in divided doses, or on an alternate-day schedule to enhance absorption and patient tolerance.
Timing & Food	For maximal absorption, the dose should be taken on an empty stomach (e.g., 1 hour before or 2 hours after a meal). However, if gastrointestinal upset occurs, it may be taken with or immediately after food.
Course Duration	To fully replenish body iron stores, treatment may continue for 3 to 6 months after hemoglobin levels have returned to normal.

Procedural Administration Rules

The usage protocol involves specific handling to prevent reduced absorption. The iron dose is typically separated by at least 2 hours from the consumption of high-tannin beverages (like tea and coffee), dairy products, and certain medications, such as antacids. Solid forms, including extended-release tablets, are intended to be swallowed whole with water and not crushed, chewed, or sucked, as this can alter the medicine’s release profile and increase the risk of staining. Liquid solutions are measured using a dedicated oral measuring device supplied with the product. These instructions support the correct operational sequence for dose delivery.

Recent Clinical Evidence

Research evidence / Overview of studies for Ironorm

Ironorm's primary component, ferrous sulfate, has been the subject of numerous Randomized Controlled Trials (RCTs) and Systematic Reviews in research exploring its application in the context of iron deficiency characterized by low hemoglobin. These studies were studied for exploring how blood markers change over time when iron is supplemented. The main outcomes the research examined included changes in Hemoglobin (Hb) concentration and Serum Ferritin, key markers of the body's iron status. The observed populations included adults, children, and pregnant women.

Research highlights the patterns measured during the study period, with studies describing the observed measurement shifts in Hemoglobin and Ferritin levels within the populations studied. However, some studies also indicated that certain older, higher-dose regimens of iron salts were associated with an increased reporting of gastrointestinal issues. This observation has led to subsequent research exploring alternative dosing schedules.

Research on Deficiency Prevention (Prophylaxis) and Special Components

The combined formulation of Ironorm was also explored in research contexts involving varying symptom burdens, specifically in studies examining its application during periods of heightened nutritional need, such as pregnancy. Large-scale Systematic Reviews and RCTs have explored the combination of iron and Folic Acid (Vitamin B9) during this period. Research examined outcomes related to the incidence of maternal anemia and, specifically for Folic Acid, the prevention of neural tube defects in infants.

Studies explored the role of the Ascorbic Acid (Vitamin C) component in the formulation, with researchers tracking the resulting changes in iron biomarkers in comparative trials. However, clinical comparison studies sometimes reported that the difference in the final levels of Hemoglobin when compared to iron-only supplementation was small or findings were mixed across different research settings.

What Remains Uncertain in the Research Record

Certainty remains low for some aspects of the clinical use of oral iron supplements, including Ironorm. For instance, the exact impact of the addition of Ascorbic Acid on achieving a significantly higher Hemoglobin level compared to iron alone appears to vary across different studies. The results apply only to the populations studied, and data for certain groups remain insufficient. The long-term effects are not fully established regarding the durability of the change in blood markers. Research is ongoing to better understand the gastrointestinal discomfort often associated with oral iron, and how different dosing schedules can affect both patient tolerance and the measured response in study populations.

How should Ironorm be stored and disposed of?

How to Store and Dispose of Ironorm

Ironorm (ferrous sulfate) must be stored according to strict regulatory conditions to ensure stability and public safety.

Storage Requirements

The product must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The container must be kept tightly closed and stored away from light, moisture, and excess heat. Liquid formulations must be protected from freezing.

Child Safety and Disposal

A critical requirement is to keep Ironorm out of the sight and reach of children. Accidental overdose of iron products is a leading cause of fatal poisoning in young children, which is why packaging must include child-resistant closures.

Expired or unused medication should not be disposed of via wastewater or household waste unless specified otherwise. The official procedure is to utilize a drug take-back program or follow instructions for disposal in household trash, mixing the medicine with an undesirable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Malta

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z